Altimmune, Inc.·4

Sep 26, 6:36 PM ET

CZEREPAK ELIZABETH 4

4 · Altimmune, Inc. · Filed Sep 26, 2017

Insider Transaction Report

Form 4
Period: 2017-09-22
CZEREPAK ELIZABETH
CFO and EVP Corp. Development
Transactions
  • Award

    Stock Options (option to buy)

    2017-09-22+62,50062,500 total
    Exercise: $2.48From: 2019-03-31Exp: 2027-09-22Common Stock, par value $0.0001 (62,500 underlying)
  • Award

    Stock Options (option to buy)

    2017-09-22+62,50062,500 total
    Exercise: $2.48From: 2017-09-22Exp: 2027-09-22Common Stock, par value $0.0001 (62,500 underlying)
Footnotes (1)
  • [F1]The option becomes exercisable, if at all, on March 31, 2019, in three equal one-third increments if the average daily closing price of Altimmune, Inc.'s common stock on Nasdaq for 10 consecutive trading days between September 22, 2017 and December 31, 2018 is at or above one of three specified thresholds, respectively.

Documents

1 file
  • 4
    edgar.xmlPrimary

    PRIMARY DOCUMENT